If You Invested in KYNTRA BIO INC (KYNB)
Looking for the current price? See the KYNB quote & overviewWhat $1,000 or $10,000 in KYNB Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jan 8, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $761 -24% |
| $10,000 | — | — | — | $7,611 -24% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for KYNB$1,000 Investment Over Time
KYNB vs S&P 500Year-by-Year Returns
KYNB annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026 | $9.50 | $7.23 | -23.9% | -23.9% |
About KYNTRA BIO INC
Pharmaceutical Preparations · NASDAQ
Kyntra Bio, Inc. is a biopharmaceutical company that develops therapies for oncology and rare disease indications. The company, formerly known as FibroGen, trades on Nasdaq under the symbol KYNB and is headquartered in San Francisco, California. Its disclosed programs center on roxadustat for anemia-related indications and FG-3246, an antibody-drug conjugate program for metastatic castration-resistant prostate cancer.
Kyntra Bio's pipeline includes roxadustat, marketed in some countries as 爱瑞卓® and EVRENZO™, which is approved in Europe, Japan, China and numerous other countries for the treatment of anemia in chronic kidney disease patients on dialysis and not on dialysis. The company continues to evaluate development of roxadustat in the United States for anemia associated with lower-risk myelodysplastic syndromes, or LR-MDS. This program places Kyntra Bio within the hematology and rare disease areas of drug development while building on an approved molecule outside the United States for CKD anemia.
The company's oncology program is built around FG-3246, also known as FOR46, a first-in-class antibody-drug conjugate targeting CD46. FG-3246 is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. Kyntra Bio also reports an associated biomarker program, FG-3180, a CD46-targeted PET imaging agent intended to support the FG-3246 development program.
Kyntra Bio's operating model is that of a clinical-stage and development-focused biotechnology company. Its recurring activities include clinical development, regulatory interactions, data presentations at medical conferences, and financial reporting tied to research and development spending. The company's public disclosures also reflect its transition from the former FibroGen identity to Kyntra Bio and its focus on a narrower set of oncology and rare disease assets.
As a public biotechnology issuer, Kyntra Bio's corporate record includes updates on pipeline development, quarterly and annual financial results, proxy governance matters, equity compensation, and Nasdaq listing compliance. These disclosures document both the scientific focus of its drug candidates and the capital, governance, and reporting requirements associated with a development-stage public biopharmaceutical company.
Frequently Asked Questions
KYNTRA BIO INC investment returns
How much would $1,000 invested in KYNTRA BIO INC be worth today?
Limited historical data is available for KYNB. The stock has been trading since 2026-01-08.
Has KYNTRA BIO INC outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare KYNB performance over available time periods.
What is KYNTRA BIO INC's average annual return?
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
